Ocular findings in asymptomatic patients with primary antiphospholipid syndrome

Abstract

Background

Primary antiphospholipid syndrome (PAPS) is characterized by the presence of antiphospholipid antibodies (aPL), repetitive fetal loss, and arterial/venous thrombosis and no association with other autoimmune rheumatic disease. Ocular involvement can also occur including retinal vascular thrombosis and neuro-ophthalmological manifestations, such as optic neuropathy and amaurosis fugax. Early detection of ocular changes is crucial to minimize functional loss.

Purpose

To perform a multimodal evaluation, including the use of Optical Coherence Angiotomography (OCTA), in patients with PAPS without ocular complaints and compare with healthy individuals.

Methods

We performed a complete structural and functional ophthalmological evaluation using OCTA and microperimetry exam in patients with PAPS, followed at a tertiary Rheumatology outpatient clinic.

Results

We included 104 eyes of 52 subjects [PAPS without ocular complaints (N = 26) and healthy individuals (N = 26)]. Among PAPS patients, 21 were female (80.8%) and 21 (80.8%) were Caucasians. PAPS manifestations were venous (65.4%), arterial thrombosis (34.6%), and obstetrical (34.6%) and all of them had lupus anticoagulant. Ophthalmologic findings were more frequent in PAPS compared to healthy individuals (19.2% vs. 0%, p = 0.05). The most common retinal change was paracentral acute middle maculopathy (PAMM) (3 patients, 5 eyes), followed by drusen (1 patient, 2 eyes) and pachychoroid pigment epitheliopathy (PPE) (1 patient, 1 eye). Hypertension and hyperlipidemia were present in 100% of the PAPS patients with PAMM, while only six patients (26.1%) with PAPS without PAMM presented these two risk factors together (p = 0.03).

Conclusions

We provide novel evidence that approximately 20% of our asymptomatic PAPS patients without ocular symptoms have ophthalmologic findings that require early identification and careful surveillance focusing on minimizing systemic and vascular risk factors.

Keywords

antiphospholipid syndrome optical coherence tomography angiography venous thrombosis arterial thrombosis retina microperimeter paracentral acute middle maculopathy

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on anupdate of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Vianna

Khamashta

Ordi-Ros

, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994; 96: 3–9.

Levine

Branch

Rauch

. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752–763.

Franco

AMdeM

Medina

FMC

Balbi

GGM

, et al. Ophthalmologic manifestations in primary antiphospholipid syndrome patients: a cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature. Lupus 2020; 29(12): 1528–1543.

Cobo-Soriano

Sánchez-Ramón

Aparicio

, et al. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 1999; 128(6): 725–732.

Radin

Sciascia

Erkan

, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum 2019; 49: 464–468.

Chylack

Wolfe

Singer

, et al. The Lens opacities classification System III. Arch Ophthalmol 1993; 111(6): 831–836.

Utz

Tang

. Ocular manifestations of the antiphospholipid syndrome. Br J Ophthalmol 2011; 95: 454–459.

Menet

Agrinier

Dufrost

, et al. Ophthalmologic manifestations in patients with antiphospholipid antibodies: beware of iatrogenic complications. Lupus [Internet] 2021; 30(11): 1799–1807.

10.

Allam

Ali

. Hypertensive uveitis: an initial presentation for primary antiphospholipid syndrome. Delta J Ophthalmol 2017; 18: 185–189.

11.

Takkar

Khokhar

Kumar

, et al. Necrotising scleritis, keratitis and uveitis in primary antiphospholipid syndrome. BMJ Case Rep 2018; 2018.

12.

Montehermoso

Mejıa

. Ophthalmological and otological manifestations in the antiphospholipid syndrome. CRR 2010; 6: 32–41.

13.

Cobo-Soriano

Sanchez-Ramon

Aparicio

, et al. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 1999; 128: 725–732.

14.

Zhu

, et al. Correction: antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis. PLoS One 2016; 11: e0157536.

15.

Rumelt

Rehany

. Central retinal artery occlusion associated with primary antiphospholipid syndrome. Eye (Lond) 1999; 13: 699–700.

16.

Sarraf

Rahimy

Fawzi

, et al. Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia. JAMA Ophthalmol 2013; 131(10): 1275–1287.

17.

Bakhoum

Freund

Dolz-Marco

, et al. Paracentral acute middle maculopathy and the ischemic cascade associated with retinal vascular occlusion. Am J Ophthalmol 2018; 195: 143–153.

18.

Scharf

Freund

Sadda

, et al. Paracentral acute middle maculopathy and the organization of the retinal capillary plexuses. Prog Retin Eye Res 2021; 81: 100884.

19.

Nakamura

Katagiri

Hayashi

, et al. Longitudinal follow-up of two patients with isolated paracentral acute middle maculopathy. Int Med Case Rep J 2019; 12: 143–149.

20.

Cringle

, et al. Functional and morphological characteristics of the retinal and choroidal vasculature. Prog Retin Eye Res 2014; 40: 53–93.

21.

Moura-Coelho

Gaspar

Ferreira

, et al. Paracentral acute middle maculopathy-review of the literature. Graefes Arch Clin Exp Ophthalmol 2020; 258(12): 2583–2596.

22.

Spaide

Fujimoto

Waheed

, et al. Optical coherence tomography angiography. Prog Retin Eye Res 2018; 64: 1–55.

23.

Scarinci

Varano

Parravano

. Retinal sensitivity loss correlates with deep capillary plexus impairment in diabetic macular ischemia. J Ophthalmol 2019; 2019: 7589841.

24.

Trese

Thanos

Yonekawa

, et al. Optical coherence tomography angiography of paracentral acute middle maculopathy associated with primary antiphospholipid syndrome. Ophthalmic Surg Lasers Imag Retina 2017; 48: 175–178.

25.

Arf

Muslubas Hocaoglu

Karacorlu

, et al. Retinal deep capillary plexus ischemia in a case with antiphospholipid syndrome. Retin Cases Brief Rep 2018; 12: 106–110.

26.

Schofield

Palestine

Pelak

, et al. Deep capillary retinal ischemia and high-titer prothrombin associated antiphospholipid antibodies: a case series of three patients. Am J Ophthalmol Case Rep 2019; 14: 105–109.

27.

Saraiva Sda

Custódio

Mazetto Bde

, et al. Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. Thromb Res 2015; 136(6): 1174–1178.

28.

Sciascia

Radin

Sanna

, et al. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatol (United Kingdom) 2018; 57(4): 661–665.

29.

Pengo

Ruffatti

Legnani

, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8(2): 237–242.

30.

Khan

Mahroo

Khan

, et al. Differentiating drusen: drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Prog Retin Eye Res 2016; 53: 70–106.

31.

Gallego-Pinazo

Dolz-Marco

Gómez-Ulla

, et al. Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol 2014; 3(4): 111–115.

32.

Cheung

CMG

Lee

Koizumi

, et al. Pachychoroid disease. Eye (Lond) 2019; 33(1): 14–33.